Brief: Cocrystal Pharma Reports Favorable Results from Single-Ascending Dose Cohorts of Phase 1 Study with CDI-988
18/07/2024 13:37
July 18 (Reuters) - Cocrystal Pharma Inc COCP.O :
* COCRYSTAL PHARMA REPORTS FAVORABLE RESULTS FROM
SINGLE-ASCENDING
DOSE COHORTS OF PHASE 1 STUDY WITH CDI-988, ITS ORAL PAN-VIRAL
NOROVIRUS/CORONAVIRUS PROTEASE INHIBITOR
* COCRYSTAL PHARMA INC: ALL PARTICIPANTS COMPLETED STUDY
WITH NO
DISCONTINUATIONS
* COCRYSTAL PHARMA INC: NO CLINICALLY SIGNIFICANT
OBSERVATIONS
WERE NOTED IN LABORATORY ASSESSMENTS, PHYSICAL EXAMS OR
ELECTROCARDIOGRAMS
Source text for Eikon: ID:nGNX8g4sv8
Further company coverage: COCP.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cocrystal Pharma
See all newsBrief: Cocrystal Pharma Announces Last Subject Dosed In Phase 1b Human Challenge Study Evaluating CDI-988 For Norovirus Prevention And Treatment
Cocrystal Pharma Inc reports results for the quarter ended June 30 - Earnings Summary
Cocrystal Pharma Inc expected to post a loss of 16 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Medtronic, Macy's, USA Rare Earth
U.S. STOCKS ON THE MOVE-USA Rare Earth, MiniMed, Rent the Runway